← All trials
NCT06584799
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2024
- Primary completion
- Jan 31, 2025
- Completion date
- Feb 28, 2025
- First posted
- Sep 5, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 150
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pirogov Russian National Research Medical UniversityLead sponsor
- Pirogov Russian National Research Medical UniversitySponsor investigator
- Pirogov Russian National Research Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.